Dec 9 (Reuters) - CVS Health (CVS) on Tuesday forecast 2026 profit above Wall Street estimates and this year's projected earnings, signalling steady progress in the health conglomerate's turnaround plan.
CVS stock rose 5% in early trading on Tuesday.
The company in October projected double-digit earnings growth for 2026 after raising its 2025 profit forecast for the third time.
"We are closing out 2025 with meaningful momentum across our businesses and we expect another year of strong earnings growth in 2026," said Chief Financial Officer Brian Newman on Tuesday.
The company forecast 2026 adjusted profit to be in the range of $7.00 to $7.20 per share, compared with analysts' average estimate of $7.16, according to data compiled by LSEG.
It, however, expects total revenue of at least $400 billion next year, below analysts' average estimate of $419.26 billion.
CVS also raised its 2025 adjusted profit forecast to $6.60 to $6.70 per share from $6.55 to $6.65 previously.
(Reporting by Sneha S K in Bengaluru; Editing by Shinjini Ganguli)
LATEST POSTS
- 1
Step by step instructions to Show Children the Significance of Appropriate Handshaking - 2Solid Living Tips: Experiences from a Wellness Fan
- 3This Is Canada's Only Province Without Any Bears
- 4Lily Allen 2026 'West End Girl' arena tour: How to get tickets, prices and more
- 5They died 'doing what they loved': The stories of workers in their 80s who died on the job
- Exclusive-Drugmakers raise US prices on 350 medicines despite pressure from Trump
- Scientists have found an alarming environmental impact of vast data centers
- From invasive species tracking to water security – what’s lost with federal funding cuts at US Climate Adaptation Science Centers
- Science is best communicated through identity and culture – how researchers are ensuring STEM serves their communities
- Figure out How to Explore Your Direction to the Best Dental Embed Trained professional: A Far reaching Manual
- Twins were the norm for our ancient primate ancestors − one baby at a time had evolutionary advantages
- A Manual for the Right SUV for Seniors
- Merck sees over $5 billion opportunity in Cidara's experimental flu drug
- Tributes pour in for MIT professor Nuno Loureiro amid unresolved shooting case
